Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome

Smita Vaidya

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Long-term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long-term allograft survival of APA as well as patients with APAS. Methods: During the study period from January 1, 1992 through May 31, 2009, 1625 patients with ESRD awaiting renal transplants were screened for APAS. Ninety-four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with APAS. Twenty-one patients with APAS received transplants on either low molecular weight (LMW) heparin or Coumadin as anticoagulation therapy. Of 94 patients with only ACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either ACA or APAS received renal transplants. Results: Ten-yr allograft survival of patients with APAS treated with Coumadin was similar to those treated with LMW heparin (18% vs. 20%, NS). However, those allograft survivals were significantly lower than those patients positive for ACA (28%) alone (ACA vs. LMW heparin or Coumadin p = 0.0001). Conclusion: Despite anticoagulation therapies, patients with APAS have lower long-term graft survival than those patients who have circulating ACA but no APAS.

Original languageEnglish (US)
Pages (from-to)853-856
Number of pages4
JournalClinical Transplantation
Volume26
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Antiphospholipid Syndrome
Allografts
Kidney
Anticardiolipin Antibodies
Low Molecular Weight Heparin
Warfarin
Transplants
Antiphospholipid Antibodies
Graft Survival
Chronic Kidney Failure

Keywords

  • Anti-cardiolipin antibodies
  • Antiphospholipid antibody
  • Coumadin
  • ESRD
  • Low molecular weight heparin

ASJC Scopus subject areas

  • Transplantation

Cite this

Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome. / Vaidya, Smita.

In: Clinical Transplantation, Vol. 26, No. 6, 11.2012, p. 853-856.

Research output: Contribution to journalArticle

@article{8cac61cd7ee642189578ada5b4a2eb5b,
title = "Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome",
abstract = "Background: Long-term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long-term allograft survival of APA as well as patients with APAS. Methods: During the study period from January 1, 1992 through May 31, 2009, 1625 patients with ESRD awaiting renal transplants were screened for APAS. Ninety-four (5.8{\%}) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with APAS. Twenty-one patients with APAS received transplants on either low molecular weight (LMW) heparin or Coumadin as anticoagulation therapy. Of 94 patients with only ACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either ACA or APAS received renal transplants. Results: Ten-yr allograft survival of patients with APAS treated with Coumadin was similar to those treated with LMW heparin (18{\%} vs. 20{\%}, NS). However, those allograft survivals were significantly lower than those patients positive for ACA (28{\%}) alone (ACA vs. LMW heparin or Coumadin p = 0.0001). Conclusion: Despite anticoagulation therapies, patients with APAS have lower long-term graft survival than those patients who have circulating ACA but no APAS.",
keywords = "Anti-cardiolipin antibodies, Antiphospholipid antibody, Coumadin, ESRD, Low molecular weight heparin",
author = "Smita Vaidya",
year = "2012",
month = "11",
doi = "10.1111/j.1399-0012.2012.01625.x",
language = "English (US)",
volume = "26",
pages = "853--856",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome

AU - Vaidya, Smita

PY - 2012/11

Y1 - 2012/11

N2 - Background: Long-term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long-term allograft survival of APA as well as patients with APAS. Methods: During the study period from January 1, 1992 through May 31, 2009, 1625 patients with ESRD awaiting renal transplants were screened for APAS. Ninety-four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with APAS. Twenty-one patients with APAS received transplants on either low molecular weight (LMW) heparin or Coumadin as anticoagulation therapy. Of 94 patients with only ACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either ACA or APAS received renal transplants. Results: Ten-yr allograft survival of patients with APAS treated with Coumadin was similar to those treated with LMW heparin (18% vs. 20%, NS). However, those allograft survivals were significantly lower than those patients positive for ACA (28%) alone (ACA vs. LMW heparin or Coumadin p = 0.0001). Conclusion: Despite anticoagulation therapies, patients with APAS have lower long-term graft survival than those patients who have circulating ACA but no APAS.

AB - Background: Long-term allograft survival of antiphospholipid antibody syndrome (APAS) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long-term allograft survival of APA as well as patients with APAS. Methods: During the study period from January 1, 1992 through May 31, 2009, 1625 patients with ESRD awaiting renal transplants were screened for APAS. Ninety-four (5.8%) of these patients had circulating levels of anticardiolipin antibodies (ACA) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with APAS. Twenty-one patients with APAS received transplants on either low molecular weight (LMW) heparin or Coumadin as anticoagulation therapy. Of 94 patients with only ACA, 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either ACA or APAS received renal transplants. Results: Ten-yr allograft survival of patients with APAS treated with Coumadin was similar to those treated with LMW heparin (18% vs. 20%, NS). However, those allograft survivals were significantly lower than those patients positive for ACA (28%) alone (ACA vs. LMW heparin or Coumadin p = 0.0001). Conclusion: Despite anticoagulation therapies, patients with APAS have lower long-term graft survival than those patients who have circulating ACA but no APAS.

KW - Anti-cardiolipin antibodies

KW - Antiphospholipid antibody

KW - Coumadin

KW - ESRD

KW - Low molecular weight heparin

UR - http://www.scopus.com/inward/record.url?scp=84870659161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870659161&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2012.01625.x

DO - 10.1111/j.1399-0012.2012.01625.x

M3 - Article

C2 - 22507396

AN - SCOPUS:84870659161

VL - 26

SP - 853

EP - 856

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 6

ER -